

www.LysimmuneBioscience.com

T: (929) 244-3537

E: Assaf.Raz@LysimmuneBioscience.com

## Lysimmune BioScience

Executive summary

Lysimmune Bioscience develops recombinant antibody solutions for methicillin resistant *Staphylococcus aureus* (MRSA) and other Gram-positive pathogens. The company's core lysibody technology generates superior immunity against conserved bacterial targets using highly evolved binding domains from bacteriophage origin.

**Company history:** Lysimmune BioScience was founded by Assaf Raz and Vincent A. Fischetti in 2017, as a spin-off from Dr. Fischetti's lab at Rockefeller University.

**Unmet need:** The MRSA (methicillin-resistant *Staphylococcus aureus*) market is \$1.4 billion, split 75% in the US and 25% EU and Japan. MRSA infection leads to a median increase in hospital stay of 10 days, and \$34,000 compared to antibiotic-sensitive strains.

**Lead product:** LI-03, a lysibody targeting all strains of *Staphylococcus aureus*, including antibiotic resistant variants such as MRSA and VRSA.

**Current state of development:** LI-03 has been optimized for large-scale production (at LakePharma), and is currently being tested for PK and efficacy (at Covance), with support from Tri-I TDI.

**Intellectual property:** PCT/US2017/061684 "Chimeric antibodies comprising binding domains of phage lysins, bacterial autolysins, bacteriocins, and phage tail or tail fibers"; covers several lysibodies against MRSA and other Gram-positive pathogens.

**Competition:** Directly competing products on the market are antibiotics with limited efficacy (Merck, Allergan, Pfizer). Products in the pipeline include monoclonal antibodies against limited epitopes and phage lysins.

**Industry** Biotech

Management CSO - Assaf Raz, PhD

Advisory board Head of SAB - Vincent A. Fischetti, PhD

Core advisory group Mina Pastagia, MD (clinical development)

Kenneth J. Gorelick, MD (Regulatory and Management)

**Amount of financing sought** \$5 MM (to reach IND milestone)